A novel gene therapy platform for the treatment of type 2 diabetes and obesity.

ABSTRACT: Diabetes and obesity are a growing healthcare and socioeconomic crisis of unprecedented proportions. Driven in part by the westernization of diets around the world, the prevalence of individuals with type 2 diabetes alone is projected to exceed 1.3 billion by 2050. Glucagon-like peptide 1 (GLP1) receptor agonists offer transformative therapeutic potential but are challenged by gastrointestinal side effects due to pharmacokinetic spikes from repeated injections, resulting in discontinuation rates which approach 70% by the first anniversary of treatment initiation. To overcome the repeat-injection nature of current GLP1 therapies, we developed a novel, subcutaneously injectable, lipid nanoparticle-based DNA delivery system to administer and express exendin 4 (EX4) or a modified natural GLP1

SUBMITTER: Lourie J 

PROVIDER: S-EPMC12597059 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature